Biologic therapy benralizumab (Fasenra) is associated with possible elimination or maximal reduction of oral corticosteroid (OCS) use in dependent patients with asthma, in new phase 3b data. The…
[mc4wp_form id="449"]
A collection of articles published at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this week would indicate that patients with asthma may not…
Omalizumab (Xolair) benefitted sleep disturbance among patients with nasal polyposis over a span of 76 weeks, according to new data presented at the American Academy of Allergy, Asthma…
Tezepelumab, an investigative monoclonal antibody therapy that inhibits the thymic stromal lymphopoietin (TSLP), was associated with clinically meaningful exacerbation reductions among patients with severe asthma at varied eosinophil…
At the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this weekend, a late-breaking poster showed just more than half (57%) of pediatric patients with…
The US Food and Drug Administration (FDA) has accepted Merck’s New Drug Application (NDA) for gefapixant—an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory…
A survey of patients previously hospitalized for COVID-19 showed a majority were still suffering from symptoms including fatigue and changes to livelihood due to affected breathing, 6 months…
While idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis, it is still considered a rare disease in need of new treatments. However, researchers are…
Masks have become a key mitigation piece in the fight to stop the spread of COVID-19. However, there is some concern regarding the use of masks for individuals…
New insight into how dupilumab treats symptoms of chronic rhinosinusitis with nasal polyps(CRSwNP) points to the potential of the commonly used drug. A team, led by Claus Bachert,…